title: Pentoxifylline in human immunodeficiency virus- positive tuberculosis: safety at 4 years.
authors.forename: R S
authors.initials: RS
authors.lastname: Wallis
authors.forename: J L
authors.initials: JL
authors.lastname: Johnson
authors.forename: A
authors.initials: A
authors.lastname: Okwera
authors.forename: P
authors.initials: P
authors.lastname: Nsubuga
authors.forename: C C
authors.initials: CC
authors.lastname: Whalen
authors.forename: R D
authors.initials: RD
authors.lastname: Mugerwa
authors.forename: J J
authors.initials: JJ
authors.lastname: Ellner
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000401:mortality; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D010431:Pentoxifylline / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012449:Safety; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000401:mortality; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline